Efficacy Study of Arbaclofen to Treat Spasticity in Multiple Sclerosis

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Osmotica Pharmaceutical Corp.
ClinicalTrials.gov Identifier:
NCT01743651
First received: November 28, 2012
Last updated: May 27, 2014
Last verified: May 2014
  Purpose

This is a multicenter, randomized (1:1:1), double-blind, active and placebo controlled, parallel group study to evaluate safety, tolerability and efficacy of oral arbaclofen in MS patients with spasticity.

Eligible subjects will be removed from anti-spasticity mediations for at least one week and then begin study drug treatment with daily doses increasing up to the target dose which will then be maintained for at least 12 weeks. A down-titration will then occur over two weeks with the final study visit occuring at 19 weeks from start of achieving the target dose or 22 weeks from the Study Visit 1.


Condition Intervention Phase
Spasticity
Multiple Sclerosis
Drug: arbaclofen
Drug: baclofen
Drug: Placebo
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: A Randomized, Double-Blind, Parallel Group Study to Compare the Safety and Efficacy Arbaclofen ER Tablets to Placebo and Baclofen Tablets, USP for the Treatment of Spasticity in Patients With Multiple Sclerosis

Resource links provided by NLM:


Further study details as provided by Osmotica Pharmaceutical Corp.:

Primary Outcome Measures:
  • Efficacy as determined by Total Numeric Transformed Modified Ashworth scale (TNmAS) in the most affected limb. [ Time Frame: Change in baseline from Visit 1 through Visit 9 (120 days) or end of treatment ] [ Designated as safety issue: No ]
    Change from baseline through end of treatment in the pre-dose, morning TNmAS of the most affected limb. The most affected limb is determined at baseline using the sum of scores for three major motor groups. High scores indicate more severe spasticity.

  • Clinical Global Impression of Change (CGIC) through end of treatment [ Time Frame: Visit 9 (120 days) or end of study ] [ Designated as safety issue: No ]
    The CGIC is a global rating scale that captures the investigator's assessment of the subject's change in overall functional performance since starting the study. Scores range from -3 (significant worsening) to +3 (significant improvement.


Secondary Outcome Measures:
  • Changes in the Multiple Sclerosis Spasticity Scale (MSSS-88) [ Time Frame: Baseline through Visit 9 (120 days) ] [ Designated as safety issue: No ]
    This MSSS-88 is a self-administered questionnaire for the subject to assess overall functional performance and sense of impairment with respect to the level of spasticity.

  • Changes in the TNmAS for the most affected limb [ Time Frame: From baseline to visits 4 (22 days), 5 (36 days), 6 (50 days), 7 (71 days), and 9 (120 days) ] [ Designated as safety issue: No ]
    The modified Ashworth Scale is a six (6)-point rating scale that measures abnormality in tone or the resistance to passive movements. Measurements are made in three muscle groups of each limb. The most affect limb is determined at baseline, based on the sum of scores from each limb. Higher scores indicate more severe spasticity.

  • Changes in the TNmAS for the sum of all limbs [ Time Frame: Baseline to visits 4 (22 days), 5 (36 days), 6 (50 days), 7 (71 days), and 9 (120 days) ] [ Designated as safety issue: No ]
    The sums of scores from all limbs are compared to the baseline sum. Higher scores indicate more severe spasticity.

  • Changes in Expanded Disability Status Score (EDSS) [ Time Frame: Baseline to Visit 9 (120 Days) ] [ Designated as safety issue: No ]
    The EDSS is based on an examination by a neurologist with a scale that ranges from zero (0) to ten (10) in half point (0.5) unit increments. Higher scores represent higher levels of disability.

  • Changes in the Lower Extremity Manual Muscle Testing (LEMMT) Scale [ Time Frame: Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days) ] [ Designated as safety issue: Yes ]
    The LEMMT Scale is an evaluation of the function and strength of individual muscles and muscle groups based on effective performance of limb movement in relation to the forces of gravity and manual resistance. Maximum muscular strength is the maximum amount of tension or force that a muscle or muscle group can voluntarily exert in one maximal effort. Scores for each muscle or muscle group range from 0 (no detectable activity) to 5 (normal activity).

  • Changes in Epworth Sleepiness Scale (ESS) [ Time Frame: Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days) ] [ Designated as safety issue: Yes ]
    The ESS is used to determine the level of daytime sleepiness. The questionnaire asks the subject to rate his or her probability of falling asleep on a scale of increasing probability from 0 to 3 in eight different situations.

  • Changes in the subject-recorded mean daily Drowsiness Numerical Rating Scale (DNRS)score for the day prior to each visit [ Time Frame: Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days) ] [ Designated as safety issue: Yes ]
    Drowsiness will be reported by the subject using a numerical rating scale with a range of zero (0; no drowsiness) to ten (10; worst possible drowsiness). Scores will be recorded every 3 hours during the day before each designated visit.

  • Changes in the Urinary Symptom Profile (USP) Scale [ Time Frame: Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) and Visit 9 (120 days) ] [ Designated as safety issue: Yes ]
    The USP is a Health-Related Quality of Life questionnaire composed of 13 items assessing urinary symptoms in adults with stress, urge, overactive bladder, or urinary obstructive symptoms.

  • Clinical Global Impression of Change (CGIC) [ Time Frame: Baseline to Visit 4 (22 days), Visit 5 (36 days) Visit 6 (50 days) Visit 7 (71 days) ] [ Designated as safety issue: No ]
    The CGIC scores will be recorded at the designated intervals prior to Visit 9 (end of study)


Enrollment: 353
Study Start Date: November 2012
Study Completion Date: April 2014
Primary Completion Date: April 2014 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Placebo Comparator: Placebo
Placebo
Drug: Placebo
arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
Active Comparator: Baclofen
Baclofen
Drug: arbaclofen
10 mg, 15 mg or 20 mg arbaclofen ER tablets administered orally 2 times per day
Drug: Placebo
arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day
Experimental: Arbaclofen
Arbaclofen
Drug: baclofen
20 mg, 30 mg or 40 mg baclofen administered orally 4 times per day
Drug: Placebo
arbaclofen image matched placebo tablets administered orally 2 times/day or baclofen image matched placebo capsules administered orally 4 times/day

  Eligibility

Ages Eligible for Study:   18 Years to 65 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients (male or female) 18 to 65 years of age, inclusive, at the time of dosing
  • Have an established diagnosis (per McDonald Criteria) of Multiple Sclerosis (either relapsing remitting or secondary progressive course), that manifests spasticity for at least 6 months
  • Spasticity due to MS as shown by a TNmAS score equal or greater than six (≥6) in the most affected limb.
  • EDSS equal or greater than 3.0
  • If receiving disease-modifying medications, these must have been at a stable dose for at least three (3) months prior to screening, and the subject must be willing to maintain this treatment for the duration of the study
  • Stable regimen for at least thirty (30) days prior to study entry for all medications and non-pharmacological therapies that are intended to alleviate spasticity
  • Absence of infections, peripheral vascular disease, painful contractures, advanced arthritis, or other conditions that hinder evaluation of joint movement
  • Have a creatinine clearance, as calculated by Glomerular Filtration Rate using the Modification of Diet in Renal Disease (MDRD) Study equation, greater than 60mL/min.
  • Use of a medically highly effective of birth control during the study and for ninety (90) days thereafter for women of child-bearing potential (including female subjects and female partners of non-sterile male subjects)
  • Willing to allow his or her general practitioner and consultant, if appropriate, to be notified of participation in the study

Exclusion Criteria:

  • Any concomitant disease or disorder that has symptoms of spasticity or that may influence the subject's level of spasticity
  • Inability to rate their level of spasticity or distinguish it from other MS symptoms
  • Acute MS exacerbation requiring treatment within twelve (12) weeks of screening
  • Use of intravenous methylprednisolone within the twelve (12) weeks before visit 1
  • Concomitant use of medications that would potentially interfere with the actions of the study medication or outcome variables
  • Use of botulinum toxin A or B within six (6) months of visit 1
  • History of allergy to baclofen or any inactive component of test or reference formulation
  • Pregnancy, lactation or planned pregnancy during the course of the study and for three (3) months thereafter.
  • History of unstable psychiatric disease, or current signs and symptoms of significant medical disorders such as severe, progressive, or uncontrolled pulmonary, cardiac, gastrointestinal, hepatic, renal, genitourinary, hematological, endocrine, immunologic, or neurological disease
  • History of seizures
  • Current significant cognitive deficit, severe or untreated anxiety, severe or untreated depression
  • Subjects with abnormal micturition that requires indwelling or intermittent catheterization or with lower urinary tract symptoms (LUTS) that result in a score greater than twenty-six (>26) in the Baseline USP© questionnaire
  • Current malignancy or history of malignancy that has not been in remission for more than five (5) years, except effectively treated basal cell skin carcinoma
  • Any other significant disease, disorder or significant laboratory finding which, in the opinion of the investigator, put the subject at risk because of participation, influence the result of the study, or affect the subject's ability to participate
  • Planned elective surgery or other procedures requiring general anesthesia during the study
  • Subject who is inappropriate for placebo medication in the judgment of the Investigator
  • History of substance abuse within the past twelve (12) months
  • Current chronic use of long acting opioids or round the clock use of short acting opioids for the treatment of pain
  • Participation in another research study within thirty (30) days of Screening
  • Patients who are uncooperative or unwilling to sign consent form
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01743651

  Show 48 Study Locations
Sponsors and Collaborators
Osmotica Pharmaceutical Corp.
Investigators
Study Chair: Praveen Tyle, PhD Osmotica Pharmaceutical
  More Information

Additional Information:
No publications provided

Responsible Party: Osmotica Pharmaceutical Corp.
ClinicalTrials.gov Identifier: NCT01743651     History of Changes
Other Study ID Numbers: OS440-3002
Study First Received: November 28, 2012
Last Updated: May 27, 2014
Health Authority: United States: Food and Drug Administration
Russia: Ministry of Health of the Russian Federation
Ukraine: Ministry of Health

Keywords provided by Osmotica Pharmaceutical Corp.:
spasticity
multiple sclerosis
arbaclofen

Additional relevant MeSH terms:
Multiple Sclerosis
Muscle Spasticity
Sclerosis
Autoimmune Diseases
Autoimmune Diseases of the Nervous System
Demyelinating Autoimmune Diseases, CNS
Demyelinating Diseases
Immune System Diseases
Muscle Hypertonia
Muscular Diseases
Musculoskeletal Diseases
Nervous System Diseases
Neurologic Manifestations
Neuromuscular Manifestations
Pathologic Processes
Signs and Symptoms

ClinicalTrials.gov processed this record on October 23, 2014